Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the research, development, production, and commercialization of biotherapeutics to address life-threatening diseases across various indications.
Incorporating recombinant DNA technologies together with innovative bio-manufacturing practices, Gennova is transforming healthcare by creating efficient and effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology and oncology segments. The company manufactures its recombinant products using bacterial, mammalian and yeast-based expression platforms. Till date, Gennova has commercialized 7 products.
Through innovation driven bio-manufacturing, Gennova became the first biotechnology company in India to launch the biosimilar of the 3rd generation thrombolytic protein, Tenecteplase (TNK-tPA), thereby catering to the unmet need in cardiovascular diseases. Carrying on with its innovation to transform healthcare, after a decade long effort, Gennova launched Tenectase®, which is a pioneering work, where first time globally a 3rd generation thrombolytic was approved for stroke. Gennova’s innovation, recognized by the Department of Biotechnology (DBT), Govt. of India for the “Biotech product, process development, and commercialization award 2019 (under Organization category)”, in addition to securing global patents for this innovation in key geographical regions, including USA and EU. Furthermore, this ‘Make in India’ initiative product has found its way in the list of drugs for emergency care for stroke management in the – ‘Guidelines for Prevention and Management of Stroke – 2019’, issued by the Ministry of Health and Family Welfare, Govt. of India.
Central to Gennova’s business is its R&D unit for research on innovative bio-manufacturing processes and the development of the company’s pipeline products. Gennova has also established itself as a preferred research and cGMP manufacturing partner in the area of vaccines and adjuvants.
